BOIRON: insider trades · France · AMF

About BOIRON

BOIRON is a leading French pharmaceutical group historically specialized in homeopathy and listed on Euronext Paris under ISIN FR0000061129 (ticker BOI). The company was founded in 1932, when pharmacists Jean and Henri Boiron started producing homeopathic medicines to meet physicians’ demand for high-quality products. Headquartered in Messimy, in the Rhône region near Lyon, BOIRON combines a strong French industrial base with an international commercial footprint supported by subsidiaries and distributor networks. The company’s official materials also note that homeopathy was incorporated into the French pharmacopoeia in 1965, later into the U.S. pharmacopoeia in 1982 and the European pharmacopoeia in 1995. BOIRON’s core business remains homeopathic healthcare products. Its portfolio is built around non-proprietary homeopathic medicines, homeopathic specialties and, more recently, other health products. The group presents itself as a global expert in homeopathy, with more than 90 years of experience, and emphasizes pharmaceutical-grade manufacturing, rigorous quality control and traceability. One notable feature of the business model is its control over the sourcing and production chain: the company states that a large share of its plant stocks comes from Europe, mainly France. That industrial discipline is a key competitive advantage in a highly regulated and niche market. Geographically, BOIRON is not limited to its domestic market. Although France remains its historic base, the group reports meaningful sales in Europe outside France, North America and other countries, showing a diversified international commercial presence. Recent commercial disclosures highlight that sales are split across these regions, which helps reduce dependence on any single market and reflects the company’s long-standing export orientation. This international reach is particularly important for a company whose brand is closely associated with homeopathy and pharmacy-driven distribution. From a corporate and shareholder standpoint, BOIRON is a notable family-controlled listed company in the French healthcare universe. In 2023, the family shareholders announced their intention to launch a simplified tender offer, followed by the definitive transfer of majority control to BOIRON Développement in 2024. The group also published its 2024 annual financial report, underlining its ongoing regulatory disclosure and market presence. Overall, BOIRON can be viewed as a defensive healthcare stock with a distinctive positioning at the intersection of pharmacy, homeopathic medicines and health solutions.